These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22178569)

  • 41. Chronic proton pump inhibitor therapy and the risk of colorectal cancer.
    Yang YX; Hennessy S; Propert K; Hwang WT; Sedarat A; Lewis JD
    Gastroenterology; 2007 Sep; 133(3):748-54. PubMed ID: 17678926
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of metformin in patients with prostate cancer and the risk of death.
    Bensimon L; Yin H; Suissa S; Pollak MN; Azoulay L
    Cancer Epidemiol Biomarkers Prev; 2014 Oct; 23(10):2111-8. PubMed ID: 25017246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.
    Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM; Chan KA
    Hepatology; 2012 May; 55(5):1462-72. PubMed ID: 22135104
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of metformin and risk of breast and colorectal cancer.
    Rennert G; Rennert HS; Gronich N; Pinchev M; Gruber SB
    Diabetes Res Clin Pract; 2020 Jul; 165():108232. PubMed ID: 32446797
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer.
    Lee JH; Jeon SM; Hong SP; Cheon JH; Kim TI; Kim WH
    Dig Liver Dis; 2012 Dec; 44(12):1042-7. PubMed ID: 22789400
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes.
    Hagberg KW; McGlynn KA; Sahasrabuddhe VV; Jick S
    Br J Cancer; 2014 Oct; 111(9):1710-7. PubMed ID: 25093492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study.
    Vinogradova Y; Hippisley-Cox J; Coupland C; Logan RF
    Gastroenterology; 2007 Aug; 133(2):393-402. PubMed ID: 17681160
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metformin use and survival from lung cancer: A population-based cohort study.
    Menamin ÚC; Cardwell CR; Hughes CM; Murray LM
    Lung Cancer; 2016 Apr; 94():35-9. PubMed ID: 26973204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.
    Bo S; Ciccone G; Rosato R; Villois P; Appendino G; Ghigo E; Grassi G
    Diabetes Obes Metab; 2012 Jan; 14(1):23-9. PubMed ID: 21812892
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.
    Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
    Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan.
    Tseng CH
    Gynecol Oncol; 2015 Jul; 138(1):147-53. PubMed ID: 25913129
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Positive effect of metformin treatment in colorectal cancer patients with type 2 diabetes: national cohort study.
    Dulskas A; Patasius A; Linkeviciute-Ulinskiene D; Zabuliene L; Urbonas V; Smailyte G
    Eur J Cancer Prev; 2020 Jul; 29(4):289-293. PubMed ID: 31567536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis.
    Liu F; Yan L; Wang Z; Lu Y; Chu Y; Li X; Liu Y; Rui D; Nie S; Xiang H
    Oncotarget; 2017 Feb; 8(9):16017-16026. PubMed ID: 27926481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.
    Yang YX; Hennessy S; Lewis JD
    Gastroenterology; 2004 Oct; 127(4):1044-50. PubMed ID: 15480982
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of thiazolidinediones and fracture risk.
    Meier C; Kraenzlin ME; Bodmer M; Jick SS; Jick H; Meier CR
    Arch Intern Med; 2008 Apr; 168(8):820-5. PubMed ID: 18443256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Filion KB; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):343-50. PubMed ID: 19998318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large US administrative claims database.
    Simeone JC; Quilliam BJ
    Ann Pharmacother; 2012 Feb; 46(2):157-68. PubMed ID: 22234990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship between metformin therapy and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis.
    Yang WT; Yang HJ; Zhou JG; Liu JL
    Int J Colorectal Dis; 2020 Nov; 35(11):2117-2131. PubMed ID: 32720184
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diabetes, metformin use, and colorectal cancer survival in postmenopausal women.
    Cossor FI; Adams-Campbell LL; Chlebowski RT; Gunter MJ; Johnson K; Martell RE; McTiernan A; Simon MS; Rohan T; Wallace RB; Paulus JK
    Cancer Epidemiol; 2013 Oct; 37(5):742-9. PubMed ID: 23773299
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis.
    Zhang ZJ; Zheng ZJ; Kan H; Song Y; Cui W; Zhao G; Kip KE
    Diabetes Care; 2011 Oct; 34(10):2323-8. PubMed ID: 21949223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.